Targeting epigenetics in diabetic cardiomyopathy: Therapeutic potential of flavonoids

Zhou, Yutong; Suo, Wendong; Zhang, Xinai; Yang, Yanan; Zhao, Wenshuo; Li, Hong; Ni, Qing

doi:10.1016/j.biopha.2022.114025

Cited by 18 publications

(12 citation statements)

References 202 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In recent years, extensive research has shown that certain herbal extracts have potential therapeutic effects on DCM 86–91 . For instance, Schisandrin B has been found to alleviate DCM by targeting MyD88 and inhibiting MyD88‐dependent inflammation 86 .…”

Section: Recent Advances In Treatment Researchmentioning

confidence: 99%

Progress in the treatment of diabetic cardiomyopathy, a systematic review

Shou,

Li,

Fang

et al. 2024

Pharmacology Res & Perspec

View full text Add to dashboard Cite

Diabetic cardiomyopathy (DCM) is a condition characterized by myocardial dysfunction that occurs in individuals with diabetes, in the absence of coronary artery disease, valve disease, and other conventional cardiovascular risk factors such as hypertension and dyslipidemia. It is considered a significant and consequential complication of diabetes in the field of cardiovascular medicine. The primary pathological manifestations include myocardial hypertrophy, myocardial fibrosis, and impaired ventricular function, which can lead to widespread myocardial necrosis. Ultimately, this can progress to the development of heart failure, arrhythmias, and cardiogenic shock, with severe cases even resulting in sudden cardiac death. Despite several decades of both fundamental and clinical research conducted globally, there are currently no specific targeted therapies available for DCM in clinical practice, and the incidence and mortality rates of heart failure remain persistently high. Thus, this article provides an overview of the current treatment modalities and novel techniques pertaining to DCM, aiming to offer valuable insights and support to researchers dedicated to investigating this complex condition.

show abstract

Section: Recent Advances In Treatment Researchmentioning

confidence: 99%

Progress in the treatment of diabetic cardiomyopathy, a systematic review

Shou,

Li,

Fang

et al. 2024

Pharmacology Res & Perspec

View full text Add to dashboard Cite

show abstract

“…Zhou et al. recently reported that flavonoids can be used as natural epigenetic modulators for DCM management ( 106 ). They discussed the epigenetic effects of different flavonoid subtypes in DCM and summarized the existing evidence from preclinical and clinical studies.…”

Section: Pharmacological Intervention and Clinical Practicementioning

confidence: 99%

“…Therefore, regulating DNA methylation to inhibit IR may be a promising new direction for early blood glucose control and prevention of DCM progression. Zhou et al recently reported that flavonoids can be used as natural epigenetic modulators for DCM management (106). They discussed the epigenetic effects of different flavonoid subtypes in DCM and summarized the existing evidence from preclinical and clinical studies.…”

Section: A Novel Therapeutic Targetmentioning

confidence: 99%

Epigenetics of methylation modifications in diabetic cardiomyopathy

Hao

Liu²

2023

Front. Endocrinol.

View full text Add to dashboard Cite

Type 2 diabetes is one of the most common metabolic diseases with complications including diabetic cardiomyopathy and atherosclerotic cardiovascular disease. Recently, a growing body of research has revealed that the complex interplay between epigenetic changes and the environmental factors may significantly contribute to the pathogenesis of cardiovascular complications secondary to diabetes. Methylation modifications, including DNA methylation and histone methylation among others, are important in developing diabetic cardiomyopathy. Here we summarized the literatures of studies focusing on the role of DNA methylation, and histone modifications in microvascular complications of diabetes and discussed the mechanism underlying these disorders, to provide the guidance for future research toward an integrated pathophysiology and novel therapeutic strategies to treat or prevent this frequent pathological condition.

show abstract

“…At the same time, diabetes is usually accompanied by serious complications such as brain hemorrhage, stroke, and cardiovascular damage. 1 According to the latest statistics from the International Diabetes Federation, 536.6 million people aged 20–79 will have diabetes in 2021; this number will rise to 783.2 million by 2045. 2 This surge in the number of people with diabetes can have serious social implication, particularly in low- and middle-income countries.…”

Section: Introductionmentioning

confidence: 99%